

A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features

Cai Jiehao^{1†}, Xu Jing^{2†}, Lin Daojiong^{3†}, Yang zhi⁴, Xu Lei⁵, Qu Zhenghai⁵, Zhang Yuehua⁶, Zhang Hua⁷, Jia Ran², Liu pengcheng², Wang Xiangshi¹, Ge Yanling¹, Xia Aimei¹, Tian He¹, Chang Hailing¹, Wang Chuning¹, Li Jingjing¹, Wang Jianshe¹, Zeng Mei^{1*}

¹ Department of infectious diseases, Children's Hospital of Fudan University, National Children's Medical Center

² Division of virology, Department of clinical laboratory, Children's Hospital of Fudan University, National Children's Medical Center

³ Department of infectious diseases, Hainan Women and Children's Medical Center

⁴ Department of infectious diseases, Anhui Provincial Children's Hospital

⁵ Children's medical center, The Affiliated Hospital of Qingdao University

⁶ Department of pediatric infectious diseases, Haikou People's Hospital

⁷ Department of pediatrics, Sanya Central Hospital

† Equally contributed to this paper.

Corresponding Author:

Mei Zeng, MD, PhD

Department of Infectious Diseases, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai 201102, China.

E-mail: zengmeigao@aliyun.com;

Abstract

We first described the 2019 novel coronavirus infection in 10 children occurring in areas other than Wuhan. The coronavirus diseases in children are usually mild and epidemiological exposure is a key clue to recognize pediatric case. Prolonged virus shedding is observed in respiratory tract and feces at the convalescent stage.

Key word: 2019 novel coronavirus; coronavirus diseases; children

Introduction

A novel coronavirus (2019-nCoV) was identified as the causative agent associated with a cluster of cases of pneumonia detected in Wuhan City by Chinese authorities on 7 January [1]. Since the discovery of 2019-nCoV, the virus has been diagnosed quickly [2,3]. With the number of people confirmed with 2019-nCoV rising rapidly in Wuhan and increasing outside of Wuhan and China, WHO declared that the outbreak of 2019-nCoV constitutes a Public Health Emergency of International Concern on 30 January 2020 [4]. By 11 February 2020, 44,672 confirmed cases were reported in China with 8,255 (18.5%) severe cases and 1023 (2.3%) deaths, and 395 confirmed cases with 1 death were reported in 24 countries outside of China [5,6]. Thus far, the notifiable cases were mostly among adults, with pediatric cases rarely reported [7,8]. The clinical profiles of 2019-nCoV infection in children is unknown. Herein, we reported the clinical and epidemiological features in children with coronavirus diseases (COVID) in China.

Method

Between 19 January and 3 February, 2020, a total of ten children with confirmed 2019-nCoV infection were admitted to the Children's Hospital in Shanghai, Hainan, Hefei in Anhui province, and Qingdao in Shandong province. According to China CDC protocol for detection 2019-nCoV, a duplex one-step real-time RT-PCR was performed to confirm 2019-nCoV infection at the local CDC reference laboratory. If respiratory samples obtained from patients were successfully tested positive by both open reading frame 1ab gene and nucleocapsid protein gene, the specimens were considered as positive and the case was considered to be laboratory-confirmed. A cycle threshold value less than 35 was defined as a positive test. All pediatric cases were hospitalized for the screening of 2019-nCoV infection when

they were considered as suspected cases based on the following two criteria: having an epidemiological link to adult cases or an exposure to Wuhan or other epidemic areas in Hubei province and presenting with acute fever and or respiratory symptoms. All patients were admitted to the isolation ward within 2 days after illness onset and nasopharyngeal and throat swabs were collected immediately for the detection of 2019-nCoV. At the meantime, influenza virus A and B were routinely tested on respiratory swab by colloidal gold assay for all patients.

Results

The detailed information on patients was shown in Table. Seven (70%) children were local residents, 2 (20%) were from Wuhan and 1 (10%) was from Xiaogan (an endemic area 50 kilometers far away from Wuhan). Eight (80%) children had direct contact with adult patients with 2019-nCoV infection who had a history of travel to Wuhan or contact with persons from Wuhan. Exposure setting included household exposure in 7 patients (70%), endemic area exposure in 2 patients (20%), and bus travelling exposure in 1 (10%) patient who had contact with 2 adult travellers from Wuhan who already had mild respiratory symptoms during the bus travelling and were confirmed with COVID after returning to Wuhan. Among seven children exposed to household adult cases, the number of secondary symptomatic cases including the child ranged from 1 to 4 (mean: 2.43). For the 3-month-old infant (patient 7 in Table), her parents developed symptomatic COVID 7 days after they looked after the sick baby without protection measures. The interval between symptom onset and exposure to index symptomatic case ranged from 2 to 10 days (mean: 6.5 days) and the interval between symptom onset and departure from endemic areas was 1 day and 9 days.

The 10 patients were aged 3-131 months (mean: 74 months) and the ratio of male to female was 1:1.5. Eight (80%) patients had fever, 6 (60%) had cough, 4 (40%) had sore throat, 3 (30%) had stuffy nose and 2 (20%) had sneezing and rhinorrhea. None of patients had diarrhea or dyspnea during the course of illness. Fever resolved 24 hours after fever onset with the peak of fever ranging from 37.7°C to 39.2°C. Chest radiograph revealed unilateral patchy infiltrate in 4 (40%) of 10 patients. The laboratory findings showed (median): white blood cell count $7.35 \times 10^9/L$, C-reactive protein 7.5 mg/L, procalcitonin 0.07 ng/dL, creatine kinase-MB 23 U/L, alanine aminotransferase 18.5 U/L, aspartate aminotransferase 27.7 U/L, urea 3.1 mmol/L, creatinine 35.5 $\mu\text{mol/L}$, lactate dehydrogenase 25 U/L and D-dimer 0.45 $\mu\text{g/mL}$; influenza virus A and B were all negative. All patients received symptomatic treatment with no need of oxygen therapy and a few of patients with pneumonia received empirical antibiotic therapy. As of 19 February, all patients had been discharged when they recovered uneventfully with 2 consecutive respiratory samples tested negative for 2019-nCoV RNA.

2019-nCoV RNA was detected in nasopharyngeal and throat swabs from all patients within 4-48 hours after symptom onset. 2019-nCoV RNA in nasopharyngeal/throat swabs was undetectable within 6-22 days (mean: 12 days) after illness onset. Six patients had fecal samples tested for 2019-nCoV RNA within 3-13 days after illness onset and 5 (83.3%) showed positivity (Of note, fecal sample from patient 2 was obtained on day 10 after illness onset and showed negativity). As of 19 February, these 5 patients still have 2019-nCoV RNA detected in feces within 18-30 days after illness onset and are under close follow-up. Five patients had urine and serum samples tested for 2019-nCoV RNA within 2-3 days after illness onset and all showed negativity.

Discussion

This is the first case series report on 2019-nCoV infection in children. Our preliminary clinical findings showed that children with COVID usually presented with mild respiratory infections, as compared with adult cases [9]. For pediatric patients, fever and mild cough are common symptoms at disease onset. For mild case, fever is brief and resolved rapidly. A few of patients presenting with/without cough also showed radiographic evidence of patchy infiltrate at symptom onset. In one study of a family cluster, an asymptomatic 10-year-old child infected with 2019-nCoV due to household exposure had radiological ground-glass lung opacities [7]. Radiographic evidence of pneumonia was a characteristics of 2019-nCoV infection at the earliest stage of infection, thus, close observation is very necessary for a child with either mild symptomatic or asymptomatic infection. We don't recommend use of antiviral agents for the treatment of self-limited non-severe COVID because no evidence has shown the effectiveness of antiviral agents currently available. Influenza virus screening is necessary to rule out the possible coinfection considering the seasonal overlap between influenza and COVID. Empirical antibiotic initiation is not recommended for treatment of non-severe 2019-nCoV-associated pneumonia without evidence of superbacterial infection. By 22 January 2020, all notifiable COVID cases and severe cases were aged ≥ 15 years old in Wuhan [9, 10]. In theory, children are also susceptible to 2019-nCoV and mild or atypical cases were largely underdiagnosed according to the initial screening criteria which focused on suspected pneumonia case [2].

The epidemiological evidence has demonstrated that COVID can be transmitted from person to person and the basic reproductive number was estimated to be 2.2 [10]. We observed the mean number of secondary symptomatic cases in household exposure setting was 2.43. Our findings highly support the evidence of human-to-human transmission of COVID. All pediatric patients had an epidemiological

link directly or indirectly to Wuhan or other endemic area of Hubei, where the outbreak of COVID originated and is ongoing. Most of pediatric cases occurring outside of Wuhan were secondary cases after exposure to adult cases through household contact or travel contact. However, we can not neglect the potential risk of transmission from the infected child to adult contacts, as shown in patient 7. Thus, personal medical protection is crucial when care providers look after the infected child. The major pattern of transmission was intrafamily transmission. The general transmission pattern of COVID is similar to that of SARS and MERS in children [11, 12]. Based on our field investigation, the mean incubation period between household exposure to a symptomatic adult case and symptom onset was 6.5 days, longer than 5.4 days observed in adult cases [10]. This difference could be suggestive of longer incubation period for 2019-nCoV infection in children. Currently, these epidemiological features are a key clue to help early recognition of 2019-nCoV infection in children outside of Wuhan and take infection prevention control interventions in time.

Virus shedding in respiratory specimens is longer in children with mild COVID, which will impose a challenge for infection control. 2019-nCoV RNA was not detected in serum samples in our study. Viremia could be related to the severity of disease because 2019-nCoV RNA was detected in blood samples obtained from 15% of adult patients with pneumonia [9]. Surprisingly, we also noted a high frequency (83.3%) of 2019-nCoV RNA detection in feces in mild patients and prolonged virus RNA shedding in feces for at least 2 weeks and even more than 1 month, which raises a question concerning whether the gastrointestinal tract may be another site of viral replication. The impact on 2019-nCoV shedding in feces on transmission model and infection prevention and control should be further assessed.

The COVID epidemic is now spreading globally. Further research and surveillance are crucial to help us understand the clinical characteristics and natural history of 2019-nCoV infection in children.

Notes

Funding.

This study was supported by the grant from the National Science and Technology Major Project of China during the "13th Five-Year" Plan Period (grant number: 2017ZX10103009-007).

Potential conflicts of interest.

The authors declare that they have no conflicts of interests, financial or otherwise, related to the publication of this study.

Reference

1. World Health Organization. WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Available at: <https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china>. Accessed 11 January 2020.
2. National Health Commission of The People's Republic of China. Interim protocol of diagnosis and treatment of 2019 novel coronavirus-associated pneumonia (the second version). Available at: <http://www.nhc.gov.cn/jkj/s3577/202001/c67cfe29ecf1470e8c7fc47d3b751e88.shtml>. Accessed 18 January 2020.
3. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* **2020**; 382(8):727-33.
4. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Available at: [https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-nCov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-nCov)). Accessed 31 January 2020.
5. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi*, **2020** ;41(2):145-151.

6. World Health Organization. Novel Coronavirus(2019-nCoV) Situation Report-22. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2. Accessed 11 February 2020.
7. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* **2020**; 395(10223):514-23.
8. Cai JH, Wang XS, Ge YL, et al. The first case report of 2019 novel coronavirus infection in children in Shanghai. *Zhong Hua Er Ke Za Zhi*, **2020**, 58(00): E002-E002.
9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **2020**; 395(10223):497-506.
10. Li Q, Guan X, Wu P, Wang X, Zhou L. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* **2020** 2020-01-29.
11. Stockman LJ, Massoudi MS, Helfand R, et al. Severe acute respiratory syndrome in children. *Pediatr Infect Dis J*, **2007**; 26(1):68-74.
12. Thabet F, Chehab M, Bafaqih H, Al MS. Middle East respiratory syndrome coronavirus in children. *Saudi Med J*, **2015**, 36(4):484-486.

Table. Epidemiological and clinical features among 2019-nCoV infected children

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
Basic information										
Admission date	19 Jan	25 Jan	31 Jan	1 Feb	3 Feb	30 Jan	26 Jan	1 Feb	27 Jan	27 Jan
City	Shanghai	Shanghai	Shanghai	Shanghai	Shanghai	Qingdao	Haikou	Sanya	Sanya	Hefei
Age (month)	84	131	131	108	7	72	3	48	96	60
Sex	Male	Female	Female	Male	Female	Female	Female	Female	Male	Male
Epidemiological history										
Exposure setting	Household	Household	Epidemic area	Bus travelling*	Household	Household	Epidemic area	Household	Household	Household
Contact with index case directly	Yes	Yes	Unknown	Yes	Yes	Yes	Unknown	Yes	Yes	Yes
Index case	Father	Adult sister	Unknown	Wuhan Travellers	Grandfather	Grandmother	Unknown	Friends	Mother	Grandmother
The interval between symptom onset and exposure to index case (days)	8	7	Unknown	8	7	3	Unknown	10	2	7
Number of secondary										

symptomatic cases including the child ^{&}	1	1	1	1	3	4	3	3	3	2
Clinical characteristics										
Peak of fever (°C)	38.0	38.4	37.7	39.2	afebrile	38.5	38.2	afebrile	38.6	38.5
Duration of fever (days)	1	1	1	1		1	1			1
Cough	Yes		Yes	Yes	Yes			Yes		Yes
Sneezing				Yes	Yes					
Stuffy nose		Yes	Yes		Yes					
Rhinorrhea				Yes	Yes					
Sore throat		Yes	Yes	Yes					Yes	
Dyspnea										
Diarrhea										
Treatment										
Symptomatic treatment	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Antibiotic						Yes	Yes	Yes	Yes	Yes
Radiographic findings										

Chest X-ray	Normal	Normal	Retrocardiac Opacity on the left	Opacities in the right lung	Opacities in the right lung	Normal	1	Norma	Opacities in the right lung	Normal	Normal
Laboratory findings											
White blood cell count ($\times 10^9$ /L) ; (normal range 3.9-9.9)	16.0 \uparrow	5.9	6.7	3.2 \downarrow	8.0	6.0		9.7	5.4	11.9 \uparrow	12.5 \uparrow
Hemoglobin (g/dL) ; (normal range 11-16)	12.8	14.2	13	15.2	11.3	13		12.3	13.1	12.1	14.4
Neutrophil count ($\times 10^9$ /L) ; (normal range 2.0-7.0)	11.2 \uparrow	3.4	3.2	1.1 \downarrow	2.0	1.6 \downarrow		4.2	1.3 \downarrow	8.07	7.4
Lymphocyte count ($\times 10^9$ /L) ; (normal range 1.2-4.0)	3.2	1.7	1.2	1.7	5.1	3.7		4.2 \uparrow	3.6	2.1	3.3

Platelet count

($\times 10^9$ /L) ;
(normal range
162–341)

138	184	211	312	188	186	494↑	311	357↑	266
-----	-----	-----	-----	-----	-----	------	-----	------	-----

C-reactive
protein (mg/L) ;
(normal range
0.0–8.0)

15.0↑	8.0	16.0↑	35.0↑	8.0	7.0	5.6	0.5	3.1	4.8
-------	-----	-------	-------	-----	-----	-----	-----	-----	-----

Procalcitonin
(ng/dL) ;
(normal range
0.0–0.5)

0.07	0.03	0.08	0.07	0.12	0.03	0.07	0.02	0.05	0.09
------	------	------	------	------	------	------	------	------	------

Creatine kinase-
MB (U/L) ;
(normal range
<25)

29.0↑	14.9	42.3↑	12.3	33.0↑	13	12	27.0↑	31.0↑	19
-------	------	-------	------	-------	----	----	-------	-------	----

Alanine
aminotransferase
(U/L);
(normal range
9.0–50.0)

17.0	7.7	19.8	26.2	100↑	13.6	40.0	19.0	18.0	14.0
------	-----	------	------	------	------	------	------	------	------

Aspartate
aminotransferase
(U/L);
(normal
range15.0-40.0)

33.0	21.4	27.5	19.7	142↑	24.5	51.0↑	28.0	20.0	34.0
------	------	------	------	------	------	-------	------	------	------

Urea (mmol/L);
(normal range

3.7	4.1	3.2	3.2	1.9↓	3.8	0.5↓	2.6↓	3.0	3.0
-----	-----	-----	-----	------	-----	------	------	-----	-----

2.8–7.6)										
Creatinine ($\mu\text{mol/L}$); (normal range 21–65)	29.0	54.0	54.0	48.0	13.0↓	58.9	16.0↓	23.0	38.0	33.0
Lactate dehydrogenase (U/L) ; (normal range 110-290)	394↑	161	228	189	368↑	194	280	Normal	Normal	304↑
D-dimer ($\mu\text{g/mL}$); (normal range 0.0–0.5)	0.6↑		0.3	0.6↑		0.2	Normal			
Detection of 2019-nCoV RNA										
Nasopharyngeal/ throat swabs	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
Duration of virus shedding in respiratory swabs (days)	12	22	8	8	6	15	8	12	14	15
Stool	Positive	Negative	Positive	Positive	Positive	Not tested [#]	Positive	Not tested [#]	Not tested [#]	Not tested [#]
Duration of virus shedding in stool (days)	>30	10	>20	>19	>18	Not tested [#]	>23	Not tested [#]	Not tested [#]	Not tested [#]

Urine	Negative	Negative	Negative	Negative	Negative	Not tested [#]	Negative	Not tested [#]	Not tested [#]	Not tested [#]
Serum	Negative	Negative	Negative	Negative	Negative	Not tested [#]	Negative	Not tested [#]	Not tested [#]	Not tested [#]

***Patient 4 contacted 2 adult travellers from Wuhan who already had mild respiratory symptoms during the bus travelling and were confirmed with COVID after returning to Wuhan.**

&The number of symptomatic secondary cases included the sum of the affected child in this case series and his/her family members who were exposed a common index case and developed symptoms.

[#]Not tested means the patient's sample not being tested for 2019-nCoV RNA.